Erschienen in:
19.10.2015 | Brief Research Article
Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer
verfasst von:
M. I. Martínez-Fernández, J. L. Pérez Gracia, I. Gil-Bazo, R. Martínez-Monge
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 7/2016
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To investigate whether bon
e metastases-directed stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer (OPC).
Methods and material
OPC is usually managed with androgen deprivation therapy (ADT). Migration to castration-resistant prostate cancer will inevitably occur in the majority of these patients. There are several strategies aimed to delay the emergence of castration resistance including intermittent ADT, second generation antiandrogens (abiraterone, enzalutamide) or metastases-directed SBRT. The present report describes two cases of patients with OPC that received SBRT 24 Gy/3Rx to the solitary bony lesion after ADT failure.
Results
Both cases showed complete and durable biochemical response for 13 and 17 months, respectively.
Conclusions
SBRT can be used to delay the emergence of castration resistance and the need for systemic therapy when used after ADT failure.